Method for efficient delivery of therapeutic molecules in vitro and in vivo

Patent metadata

Field	Value
Publication number	US-11071790-B2
Application number	US-201515523321-A
Country	US
Kind code	B2
Filing date	Oct 29, 2015
Priority date	Oct 29, 2014
Publication date	Jul 27, 2021
Grant date	Jul 27, 2021

Abstract

Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

First claim

What is claimed is:

1. A method of treating deafness, associated with an autosomal dominant genetic mutation in a TMC1 gene in a patient in need thereof, comprising: administering to an inner ear of the patient a therapeutically effective amount of a chimeric molecule consisting of a membrane destabilizing domain, a gene editing agent, wherein the gene editing agent is Cas9, and a gRNA targeting a TMC1 gene, thereby treating deafness.

2. The method of claim 1 , wherein the chimeric molecule targets one or more genetic loci associated with deafness in a patient and modulates replication, expression, function or activity of the genetic locus in hair cells, stem cells, or supporting cells.

3. The method of claim 2 , wherein the one or more genetic loci comprise chromosomal abnormalities having deletions.

4. The method of claim 1 , wherein the genetic mutations further comprise one or more monogenic mutations.

5. The method of claim 1 , wherein the chimeric molecule further comprises a supercharged protein or variants thereof.

6. The method of claim 5 , wherein the supercharged protein is green fluorescent protein (s-GFP), or variants thereof.

7. The method of claim 1 , wherein the gene editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof.

8. The method of claim 1 , wherein the chimeric molecule further comprises antimicrobial or membrane destabilizing peptides linked to the s-GFP, or variants thereof.

9. The method of claim 1 , wherein the chimeric molecule is encapsulated in a cationic lipid formulation.

10. The method of claim 1 , wherein the chimeric molecule comprises any one or more sequences having a sequence identity of at least about 75% to SEQ ID NO: 95.

11. The method of claim 10 , wherein the one or more sequences comprise SEQ ID NO: 95.

Assignees

• Massachusetts Eye & Ear Infirmary
• Harvard College

Inventors

• Chen Zheng-Yi
• Liu David R
• Li Margie
• Thompson David B
• Zuris John

Classifications

• C12Y306/03008

  Ca2+-transporting ATPase (3.6.3.8) · CPC title

• C12N15/907

  in mammalian cells · CPC title

• C12N15/1137

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C12N9/14

  Hydrolases (3) · CPC title

• C12N9/1241

  Nucleotidyltransferases (2.7.7) · CPC title